Healthcare Industry News:  Prostate Cancer 

Diagnostics Oncology Personalized Medicine Personnel

 News Release - January 18, 2011

PrognosDx Announces Appointments of Dr. Garry Nolan to Board of Directors and Dr. Joseph Presti to Scientific Advisory Board

Addition of Dr. Nolan to Board of Directors and Dr. Presti to SAB Will Help Position PrognosDx as the Leader in Epigenetic Tumor Profiling for the Life Sciences Industry

PALO ALTO, Calif.--(Healthcare Sales & Marketing Network)-- PrognosDx Health, Inc., an epigenetics pioneer harnessing the predictive power of global patterns of histone modifications, announced today the appointment of Garry P. Nolan, Ph.D. as Vice Chairman.

“It has become quite clear that tumor heterogeneity is a next frontier in our attack on cancer resistance phenomenon,” said Dr. Nolan. “It’s also clear that such variability of tumor biology can be driven in large part by epigenetics. I am excited to be involved with a company that has amassed a scientific estate around molecular markers of epigenetics that are correlated with mechanistic correlates of clinical outcomes. The fact that their approaches can work with archived materials enhances the ability to use long completed studies to initiate and complete clinical trials for new drug opportunities.”

A prominent figure in the biotech industry, Dr. Nolan is a global leader in single cell analysis and the co-founder of several companies, including publicly traded Rigel Pharma (NASDAQ:RIGL ) and privately held Nodality, Inc.

PrognosDx recently strengthened its scientific advisory board (SAB) to include cancer experts Drs. Joseph C. Presti, Robert Schimke and Amato Giaccia of Stanford University, as well as industry veterans Drs. Jack Bloom and David Young of partner firm Flagship BioSciences.

“Improved markers of risk are needed for patients with Prostate Cancer,” said Dr. Presti, Associate Chair of the Division of Urology at Stanford University’s School of Medicine. “Current clinical parameters such as grade, PSA and clinical stage are limited in their ability to predict the biological behavior of a specific tumor. Epigenetic profiling may provide new insight into specific tumor biology as well as response to therapy. This technology may revolutionize our ability to prognosticate and/or treat cancer patients.”

About Epigenetics

Epigenetics refers to the regulation of genes with mechanisms other than changes to the underlying DNA sequence and such processes are widely believed to play a central role in the development and progression of almost all cancers. Such epigenetic processes are controlled by DNA methylation and histone modifications.

About PrognosDx Health, Inc.

PrognosDx Health, Inc. is commercializing novel epigenetic tests based on global histone modification patterns through technology exclusively licensed from the University of California, Los Angeles (UCLA). This platform technology has broad potential uses in the development of cancer prognostic assays, therapeutic response prediction assays, as well as research tools and reagents. The company has its headquarters in Palo Alto, California. For further information, please visit www.prognosdx.com.


Source: PrognosDx

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.